leg

By Targets:	Autophagy (2) Dopamine Receptor (13) Fluorescent Dye (1) HIV (2) Isotope-Labeled Compounds (3) Phosphodiesterase (PDE) (3)
By Research Areas:	Cancer (3) Cardiovascular Disease (3) Inflammation/Immunology (2) Neurological Disease (14)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-70081A

Sumanirole maleate 1 Publications Verification U-95666E; PNU-95666	Dopamine Receptor	Neurological Disease
Sumanirole maleate (U-95666E; PNU-95666E) is a highly selective D2 receptor full agonist with an ED₅₀ of about 46 nM. Sumanirole plays an important role in the research of Parkinson's disease and restless leg syndrome .

HY-17355

Pramipexole dihydrochloride 5 Publications Verification	Dopamine Receptor	Neurological Disease
Pramipexole dihydrochloride is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with K_is of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D₂, D₃ and D₄ receptors, respectively. Pramipexole dihydrochloride can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS) .

HY-B0410

Pramipexole 5 Publications Verification	Dopamine Receptor	Neurological Disease
Pramipexole is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with K_is of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D₂, D₃ and D₄ receptors, respectively. Pramipexole can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS) .

HY-B0410A

Pramipexole dihydrochloride hydrate 5 Publications Verification	Dopamine Receptor	Neurological Disease
Pramipexole dihydrochloride hydrate is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with K_is of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D₂, D₃ and D₄ receptors, respectively. Pramipexole dihydrochloride hydrate can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS) .

HY-N0658A

DL-Threonine	Others	Inflammation/Immunology
DL-Threonine, an essential amino acid, has the potential to treat hypostatic leg ulceration .

HY-B1170

Cyclandelate 3,5,5-Trimethylcyclohexyl mandelate	Others	Cardiovascular Disease
Cyclandelate is a vasodilator that can be used in the study of claudication, arteriosclerosis, Raynaud's disease, nocturnal leg cramps, and migraines.

HY-70081

Sumanirole PNU-95666E	Dopamine Receptor	Neurological Disease
Sumanirole (PNU-95666E) is a highly selective D2 receptor full agonist with an ED₅₀ of about 46 nM. Sumanirole plays an important role in the research of Parkinson's disease and restless leg syndrome .

HY-B0410R

Pramipexole (Standard)	Dopamine Receptor	Neurological Disease
Pramipexole (Standard) is the analytical standard of Pramipexole. This product is intended for research and analytical applications. Pramipexole is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with K_is of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D₂, D₃ and D₄ receptors, respectively. Pramipexole can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS) .

HY-B0410AR

Pramipexole dihydrochloride hydrate (Standard)	Dopamine Receptor	Neurological Disease
Pramipexole (dihydrochloride hydrate) (Standard) is the analytical standard of Pramipexole (dihydrochloride hydrate). This product is intended for research and analytical applications. Pramipexole dihydrochloride hydrate is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with Kis of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole dihydrochloride hydrate can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS) .

HY-N0658AR

DL-Threonine (Standard)	Others	Inflammation/Immunology
DL-Threonine (Standard) is the analytical standard of DL-Threonine. This product is intended for research and analytical applications. DL-Threonine, an essential amino acid, has the potential to treat hypostatic leg ulceration .

HY-136626

Z-Ala-Ala-Asn-AMC 3 Publications Verification Cbz-Ala-Ala-Asn-AMC	Fluorescent Dye	Cancer
Z-Ala-Ala-Asn-AMC (Cbz-Ala-Ala-Asn-AMC) is the legumain substrate. Overexpressed legumain in 293 HEK-Leg cells potently cleaved CBZ-Ala-Ala-Asn-AMC .

HY-13720

Pergolide LY127809 free base	Dopamine Receptor	Neurological Disease
Pergolide (LY127809 (free base)) is an ergot-derived orally active dopamine receptor agonist. Pergolide can be used for Parkinson disease research .

HY-13720S

Pergolide-d7 hydrochloride	Dopamine Receptor Isotope-Labeled Compounds	Neurological Disease
Pergolide-d₇ hydrochloride is deuterated labeled Pergolide (HY-13720). Pergolide (LY127809 (free base)) is an ergot-derived orally active dopamine receptor agonist. Pergolide can be used for Parkinson disease research .

HY-17355S

Pramipexole-d7 dihydrochloride	Isotope-Labeled Compounds Dopamine Receptor	Neurological Disease
Pramipexole-d₇ (dihydrochloride) is the deuterium labeled Pramipexole dihydrochloride. Pramipexole dihydrochloride is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with Kis of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole dihydrochloride can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS)[1][2][3].

HY-17355S1

Pramipexole-d5 dihydrochloride	Isotope-Labeled Compounds Dopamine Receptor	Neurological Disease
Pramipexole-d₅ (dihydrochloride) is deuterium labeled Pramipexole (dihydrochloride). Pramipexole dihydrochloride is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with Kis of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole dihydrochloride can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS)[1][2][3].

HY-B0410S1

Pramipexole-d5	Dopamine Receptor	Neurological Disease
Pramipexole-d₅ is the deuterium labeled Pramipexole[1]. Pramipexole is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with Kis of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS)[2][3][4].

HY-17355S2

Pramipexole-d7-1 dihydrochloride	Dopamine Receptor	Neurological Disease
Pramipexole-d₇-1 (dihydrochloride) is the deuterium labeled Pramipexole dihydrochloride[1]. Pramipexole dihydrochloride is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with Kis of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole dihydrochloride can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS)[2][3][4].

HY-B0715

Pentoxifylline Maximum Cited Publications 7 Publications Verification BL-191; PTX; Oxpentifylline	Phosphodiesterase (PDE) Autophagy HIV	Cardiovascular Disease Cancer
Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation .

HY-B0715R

Pentoxifylline (Standard) BL-191 (Standard); PTX (Standard); Oxpentifylline (Standard)	HIV Autophagy Phosphodiesterase (PDE)	Cardiovascular Disease Cancer
Pentoxifylline (Standard) is the analytical standard of Pentoxifylline. This product is intended for research and analytical applications. Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation .

HY-101490

PDE1-IN-2	Phosphodiesterase (PDE)	Neurological Disease
PDE1-IN-2 is a PDE1 inhibitor extracted from patent WO2016/55618 A1, example 31. PDE1-IN-2 has IC₅₀ values of 6 nM, 140 nM and 164 nM for PDE1C, PDE1B and PDE1A, respectvely. PDE1-IN-2 is developed for the research of neurodegenerative disorders and psychiatric disorders .

Cat. No.	Product Name

HY-L040

Anti-diabetic Compound Library	780 compounds
Diabetes mellitus, usually called diabetes, is a group of metabolic disorders characterized by a high blood sugar level over a prolonged period of time. The most common types are Type I and Type II. Type I diabetes (T1D), also called juvenile onset diabetes mellitus or insulin-dependent diabetes mellitus, is characterized by destruction of the β-cells of the pancreas and insulin is not produced, whereas type II diabetes (T2D), also called non-insulin-dependent diabetes mellitus, is characterized by a progressive impairment of insulin secretion and relative decreased sensitivity of target tissues to the action of this hormone. Type 2 diabetes accounts for the vast majority of all diabetes mellitus. Diabetes of all types can lead to complications in many parts of the body and can increase the overall risk of dying prematurely. Possible complications include kidney failure, leg amputation, vision loss and nerve damage. The pathogenesis of diabetes is complicated, and development of the safe and effective drugs against diabetes is full of challenge. Increasing studies have confirmed that the pathogenesis of diabetes is related to various signaling pathways, such as insulin signaling pathway, AMPK pathway, PPAR regulation and chromatin modification pathways. These signaling pathways have thus become the major source of the promising novel drug targets to treat metabolic diseases and diabetes. MCE Anti-diabetic Compound Library owns a unique collection of 780 compounds, which mainly target SGLT, PPAR, DPP-4, AMPK, Dipeptidyl Peptidase, Glucagon Receptor, etc. This library is a useful tool for discovery anti-diabetes drugs.

Anti-diabetic Compound Library

780 compounds

Diabetes mellitus, usually called diabetes, is a group of metabolic disorders characterized by a high blood sugar level over a prolonged period of time. The most common types are Type I and Type II. Type I diabetes (T1D), also called juvenile onset diabetes mellitus or insulin-dependent diabetes mellitus, is characterized by destruction of the β-cells of the pancreas and insulin is not produced, whereas type II diabetes (T2D), also called non-insulin-dependent diabetes mellitus, is characterized by a progressive impairment of insulin secretion and relative decreased sensitivity of target tissues to the action of this hormone. Type 2 diabetes accounts for the vast majority of all diabetes mellitus. Diabetes of all types can lead to complications in many parts of the body and can increase the overall risk of dying prematurely. Possible complications include kidney failure, leg amputation, vision loss and nerve damage.

The pathogenesis of diabetes is complicated, and development of the safe and effective drugs against diabetes is full of challenge. Increasing studies have confirmed that the pathogenesis of diabetes is related to various signaling pathways, such as insulin signaling pathway, AMPK pathway, PPAR regulation and chromatin modification pathways. These signaling pathways have thus become the major source of the promising novel drug targets to treat metabolic diseases and diabetes.

MCE Anti-diabetic Compound Library owns a unique collection of 780 compounds, which mainly target SGLT, PPAR, DPP-4, AMPK, Dipeptidyl Peptidase, Glucagon Receptor, etc. This library is a useful tool for discovery anti-diabetes drugs.

Cat. No.	Product Name	Target	Research Area

HY-136626

Z-Ala-Ala-Asn-AMC 3 Publications Verification Cbz-Ala-Ala-Asn-AMC	Fluorescent Dye	Cancer
Z-Ala-Ala-Asn-AMC (Cbz-Ala-Ala-Asn-AMC) is the legumain substrate. Overexpressed legumain in 293 HEK-Leg cells potently cleaved CBZ-Ala-Ala-Asn-AMC .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0658A

DL-Threonine	Structural Classification other families Microorganisms Classification of Application Fields Animals Source classification Amino acids Plants Inflammation/Immunology Disease Research Fields	Others
DL-Threonine, an essential amino acid, has the potential to treat hypostatic leg ulceration .

HY-B0715

Pentoxifylline 5+ Cited Publications BL-191; PTX; Oxpentifylline	Classification of Application Fields Disease Research Fields Cancer	Phosphodiesterase (PDE) Autophagy HIV
Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation .

HY-N0658AR

DL-Threonine (Standard)	Structural Classification Microorganisms other families Animals Source classification Amino acids Plants	Others
DL-Threonine (Standard) is the analytical standard of DL-Threonine. This product is intended for research and analytical applications. DL-Threonine, an essential amino acid, has the potential to treat hypostatic leg ulceration .

Cat. No.	Product Name	Chemical Structure

HY-13720S

Pergolide-d7 hydrochloride
Pergolide-d₇ hydrochloride is deuterated labeled Pergolide (HY-13720). Pergolide (LY127809 (free base)) is an ergot-derived orally active dopamine receptor agonist. Pergolide can be used for Parkinson disease research .

HY-17355S

Pramipexole-d7 dihydrochloride
Pramipexole-d₇ (dihydrochloride) is the deuterium labeled Pramipexole dihydrochloride. Pramipexole dihydrochloride is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with Kis of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole dihydrochloride can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS)[1][2][3].

Pramipexole-d7 dihydrochloride

Pramipexole-d₇ (dihydrochloride) is the deuterium labeled Pramipexole dihydrochloride. Pramipexole dihydrochloride is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with Kis of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole dihydrochloride can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS)[1][2][3].

HY-17355S1

Pramipexole-d5 dihydrochloride
Pramipexole-d₅ (dihydrochloride) is deuterium labeled Pramipexole (dihydrochloride). Pramipexole dihydrochloride is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with Kis of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole dihydrochloride can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS)[1][2][3].

Pramipexole-d5 dihydrochloride

Pramipexole-d₅ (dihydrochloride) is deuterium labeled Pramipexole (dihydrochloride). Pramipexole dihydrochloride is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with Kis of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole dihydrochloride can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS)[1][2][3].

HY-B0410S1

Pramipexole-d5
Pramipexole-d₅ is the deuterium labeled Pramipexole[1]. Pramipexole is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with Kis of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS)[2][3][4].

HY-17355S2

Pramipexole-d7-1 dihydrochloride
Pramipexole-d₇-1 (dihydrochloride) is the deuterium labeled Pramipexole dihydrochloride[1]. Pramipexole dihydrochloride is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with Kis of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole dihydrochloride can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS)[2][3][4].

Pramipexole-d7-1 dihydrochloride

Pramipexole-d₇-1 (dihydrochloride) is the deuterium labeled Pramipexole dihydrochloride[1]. Pramipexole dihydrochloride is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with Kis of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole dihydrochloride can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS)[2][3][4].

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P80404

	Galectin 3 Antibody Galectin-3; 35 kDa lectin; Carbohydrate binding protein 35; CBP 35; CBP35; GAL 3; GAL3; GAL-3; Galactose specific lectin 3; Galactose-specific lectin 3; Galactoside binding protein; Galactoside-binding protein; GALBP; Galectin3 internal gene,included; Galectin3; GALIG; GBP; IgE binding protein; IgE-binding protein; L 31; L 34; L-34 galactoside-binding lectin; L31; Laminin binding protein; Laminin-binding protein; Lectin galactose binding soluble 3; Lectin galactoside binding soluble 3; Lectin L 29; Lectin L-29; Lectin, galactose binding, soluble 3; LGALS 3; LGALS2; LGALS3; LGALS3 protein; MAC 2 antigen; Mac-2; MAC2; Macrophage galactose-specific lectin; MGC105387; leg3_HUMAN.	WB, ICC/IF, FC, IHC-P	Human, Mouse
	Galectin 3 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 26 kDa, targeting to Galectin 3. It can be used for WB,ICC/IF,FC,IHC-P assays with tag free, in the background of Human, Mouse.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Isotope-Labeled Compounds

Antibodies